Corbus Pharmaceuticals Holdings (CRBP) EBITDA (2013 - 2025)
Corbus Pharmaceuticals Holdings (CRBP) recorded quarterly EBITDA of $1.1 million in Q3 2025, up 105.87% quarter-over-quarter from -$19.2 million in Q2 2025, and down 40.88% on a YoY basis from $1.9 million in Q3 2024.
Corbus Pharmaceuticals Holdings (CRBP) EBITDA (2013 - 2025) Analysis & Trends
Corbus Pharmaceuticals Holdings' EBITDA history runs 13 years deep, the most recent figure standing at $1.1 million for Q3 2025.
- In Q3 2025, EBITDA fell 40.88% year-over-year to $1.1 million; the TTM figure through Sep 2025 stood at -$33.3 million (down 183.56% YoY), while the FY2024 annual figure was $6.3 million, up 114.19% from the prior year.
- EBITDA was $1.1 million for Q3 2025 at Corbus Pharmaceuticals Holdings, up from -$19.2 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of $1.9 million in Q3 2024 to a low of -$19.2 million in Q2 2025.
- Historically, EBITDA has averaged -$8.9 million across 5 years, with a median of -$9.5 million in 2022.
- The sharpest annual moves came in 2024 and 2025: EBITDA surged 122.21% in 2024, then sank 1297.0% in 2025.
- A 5-year view of EBITDA shows it stood at -$10.0 million in 2021, then dropped by 8.0% to -$10.8 million in 2022, then gained by 25.78% to -$8.0 million in 2023, then soared by 122.21% to $1.8 million in 2024, then plunged by 36.8% to $1.1 million in 2025.
- The last three EBITDA figures came in at $1.1 million (Q3 2025), -$19.2 million (Q2 2025), and -$17.0 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -26.92 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -13.63 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -14.44 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -752,618.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -65.83 Mn |
| 10 | Corbus Pharmaceuticals Holdings | 133.67 Mn | 105.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 1.13 Mn |
| Jun 30, 2025 | -19.15 Mn |
| Mar 31, 2025 | -17.04 Mn |
| Dec 31, 2024 | 1.78 Mn |
| Sep 30, 2024 | 1.90 Mn |
| Jun 30, 2024 | 1.60 Mn |
| Mar 31, 2024 | -7.23 Mn |
| Dec 31, 2023 | -8.01 Mn |
| Sep 30, 2023 | -10.04 Mn |
| Jun 30, 2023 | -8.74 Mn |
| Mar 31, 2023 | -17.69 Mn |
| Dec 31, 2022 | -10.80 Mn |
| Sep 30, 2022 | -8.87 Mn |
| Jun 30, 2022 | -13.20 Mn |
| Mar 31, 2022 | -9.54 Mn |
| Dec 31, 2021 | -10.00 Mn |
| Sep 30, 2021 | -2.18 Mn |
| Jun 30, 2021 | -17.12 Mn |
| Mar 31, 2021 | -16.09 Mn |
| Dec 31, 2020 | -20.81 Mn |